What the Clinical Trials Show About Cytisinicline

Last reviewed: November 15, 2026Next review due: November 2027

Key takeaways

Cytisinicline is the name used in recent US trials for cytisine, a plant-based quit-smoking medication. In two phase 3 trials with about 800 adults each, 12 weeks of treatment gave 30% to 33% abstinence at the end of treatment, against 7% to 9% on placebo. Side effects were mostly mild. The trials were funded by the developer and run in the US, so they do not tell you what to buy in Canada.

The trial reports use a longer name than the one on Canadian shelves. The ORCA-1 paper says cytisinicline is known as cytisine, a plant-based compound already marketed in Central and Eastern Europe. The newer trials tested it in the United States, where, according to the 2023 ORCA-2 abstract, it was not licensed at the time. We read the abstracts of all three trials on 15 November 2026, plus the funding statement in the ORCA-2 paper. Trial results describe groups of people, not what will happen to you, so ask a pharmacist or doctor before changing your quit plan.

What were the ORCA trials?

ORCA-1 was a phase 2b trial of 254 adults. It ran 25 days of treatment and led the authors to choose 3 mg three times daily for phase 3, citing simpler dosing, tolerability and the best continued abstinence.

ORCA-2 randomized 810 adults who smoked daily and wanted to quit, at 17 US sites. ORCA-3 repeated the design with 792 adults who smoked 10 or more cigarettes a day, at 20 US sites. Both compared 12 weeks of cytisinicline, 6 weeks of cytisinicline followed by 6 weeks of placebo, and 12 weeks of placebo. All groups received behavioral support, and quitting was confirmed with biochemical tests.

What were the quit rates?

Abstinence was measured as continuous, biochemically verified smoke-free time, which is a stricter test than asking people whether they smoked. A placebo group matters because many people quit with support alone, so the useful number is the gap between the two columns. For the 12-week course the authors measured weeks 9 to 12.

  • ORCA-2: 32.6% on cytisinicline versus 7.0% on placebo.
  • ORCA-3: 30.3% versus 9.4%.

For the 6-week course the window was weeks 3 to 6. ORCA-2 found 25.3% versus 4.4%, and ORCA-3 found 14.8% versus 6.0%. The gap between the two trials is large for the shorter course, so treat the 6-week figures as less certain than the 12-week ones.

Did the results last?

Both trials followed people to week 24. In ORCA-2, 21.1% of the 12-week group were still continuously abstinent from week 9 to week 24, against 4.8% on placebo. In ORCA-3 the figures were 20.5% and 4.2%. For the 6-week course, ORCA-3 reported 6.8% against 1.1%, and ORCA-2 reported 8.9% against 2.6%. These are not results at one year, and the abstracts we read do not give longer follow-up.

What about side effects?

In ORCA-2, nausea, abnormal dreams and insomnia occurred in less than 10% of each group. Sixteen participants, 2.9%, stopped cytisinicline because of an adverse event, and no drug-related serious adverse events occurred. ORCA-3 reported that the drug was well tolerated with no treatment-related serious adverse events, and that it reduced nicotine craving more than placebo. Trials of this size cannot rule out rare problems.

How should you read these numbers?

The ORCA-2 paper says the trial was supported by the company developing the drug, and several authors work for it. Funding by the developer does not make results wrong, but it is worth knowing. The participants were adults in US clinics who got behavioral support, which may be more than many people get at home. We have no Canadian trial of cytisinicline to report. For how cytisine is sold here, see cytisine in Canada, and for the wider menu see quit-smoking medications in Canada.

What we could not confirm

  • Whether cytisinicline is approved by Health Canada or any other regulator today. We found no Health Canada page on it and no official regulator page we could read.
  • Whether the dose and schedule of any cytisine product sold in Canada match the trial regimen.
  • Results beyond 24 weeks, and head-to-head comparisons with varenicline, which these trials did not make.
  • The full list of exclusions and the make-up of participants, because we read abstracts and one funding statement, not every table.

Health information is general and educational. It does not replace advice from a doctor, pharmacist or nurse. Read the full disclaimer.

Frequently asked questions

Is cytisinicline the same as cytisine?

The ORCA-1 paper says cytisinicline is known as cytisine. The trials tested a specific 3 mg tablet taken three times a day, so a Canadian cytisine product may differ in dose and schedule. Check the product label and ask a pharmacist.

How well did cytisinicline work in the trials?

In ORCA-2, 32.6% of people on the 12-week course had stayed smoke-free in weeks 9 to 12, against 7.0% on placebo. In ORCA-3 the figures were 30.3% and 9.4%. Everyone, including the placebo group, got behavioral support.

What were the side effects?

In ORCA-2, nausea, abnormal dreams and insomnia each occurred in less than 10% of each group, and 2.9% stopped cytisinicline because of a side effect. ORCA-3 reported no treatment-related serious adverse events.

Can I buy cytisinicline in Canada?

We found no Health Canada page about cytisinicline. Health Canada says cytisine is a natural health product that can be purchased without a prescription in Canada. See our cytisine page for what the department says.

Sources

  1. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial (ORCA-2) — JAMA, via PubMed Central. Accessed November 15, 2026.
  2. Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial (ORCA-3) — JAMA Internal Medicine, via PubMed Central. Accessed November 15, 2026.
  3. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (ORCA-1) — Nicotine & Tobacco Research, via PubMed Central. Accessed November 15, 2026.
  4. Quit with Confidence: How to quit — Health Canada. Accessed November 15, 2026.
Disclaimer: the information on this site is for general reference only. It is not medical, legal or financial advice. Laws, rates and programs change, so check the official source before you rely on any detail.